Kidney Disease

Latest News

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit  ©Tada Images/stock.adobe.com
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

November 1st 2024

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock
New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

October 23rd 2024

Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting / image credit kidneys concept ©Rasi/stock.adobe.com
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting

October 14th 2024

Bayer: Phase 2 Trial of Investigational Soluble Guanylate Cyclase Activator for Chronic Kidney Disease Begins
Bayer: Phase 2 Trial of Investigational Soluble Guanylate Cyclase Activator for Chronic Kidney Disease Begins

August 22nd 2024

FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use / Image credit: ©Peter Hansen/AdobeStock
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use

June 25th 2024

Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.